parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in salivary duct cells	0.75
chemistry Open Targets	compounds already reach it: bintrafusp alfa, trabedersen, luspatercept +1	0.81
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	3 Parkinson's papers of 782	0.82
pathways Reactome	5 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 6910

receipt 6920: TGFB2 in dopamine neurons, braak

power: full sample +0.03 (p 0.915, n 18), 95% CI -0.45 to +0.49. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.827, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.15 (p 0.549, n 18). could be the mix.
skeptic: leave-one-out range -0.08 to +0.16, sign flips 5; without severely affected donors +0.03 (p 0.915, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TGFB2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6919: TGFB2 in astrocytes, braak

power: full sample +0.06 (p 0.807, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.04 (p 0.888, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.01 (p 0.969, n 18). could be the mix.
skeptic: leave-one-out range -0.08 to +0.16, sign flips 4; without severely affected donors +0.06 (p 0.807, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TGFB2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts